Dr. Reddy’s Laboratories RDY -0.05% announced yesterday that it has launched
Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous
Use, a therapeutic equivalent generic version of IMITREX STATdosePen®
(sumatriptan succinate) 6 mg/0.5 mL in the US market on February 25, 2014,
following the approval by the United States Food & Drug Administration
(USFDA).
The IMITREX STATdosePen® (sumatriptan succinate)
brand and generic combined had U.S. sales of approximately $169 Million MAT for
the most recent twelve months ending in December 2013 according to IMS Health*.
Dr. Reddy’s Sumatriptan Injection USP, Autoinjector
System 6 mg/ 0.5 mL is available in a carton containing 2 single-dose prefilled
syringes.
Disclaimer
This press release includes forward-looking
statements, as defined in the U.S. Private Securities Litigation Reform Act of
1995. We have based these forward-looking statements on our current
expectations and projections about future events. Such statements involve known
and unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited to,
changes in local and global economic conditions, our ability to successfully
implement our strategy, the market acceptance of and demand for our products,
our growth and expansion, technological change and our exposure to market
risks. By their nature, these expectations and projections are only estimates
and could be materially different from actual results in the future.
About Dr. Reddy's
Dr. Reddy’s Laboratories Ltd. RDY -0.05% is an integrated global pharmaceutical company,
committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services and Active Ingredients,
Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of
products and services including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Major therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain management and
anti-infective. Major markets include India, USA, Russia-CIS and Europe apart
from other select geographies within Emerging Markets.
No comments:
Post a Comment